At a recent U.S. Food and Drug Administration (F.D.A.) panel, doctors argued for the removal of the black box warning on hormone treatments used to alleviate menopause symptoms. The black box warning ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Memo warns GOP not to let ObamaCare tax ...

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...

The contrast between the FDA’s clinical lens and the raw realities in the Bonafide study highlights a critical disconnect ...

A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...

A new study suggests that hormone therapy, often used to ease symptoms of menopause like hot flashes and night sweats, may ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

US health authorities are reassessing the risks of Hormone Replacement Therapy (HRT) in a meeting convened by FDA chief Marty ...

Dr. Marty Makary, the agency’s commissioner, said too many women avoid hormone therapy because the risks have been overstated ...

A groundbreaking study of nearly 45,000 people shows how a blood test measuring proteins can estimate which organs are aging ...

Ultragenyx received a Complete Response Letter from the FDA regarding its UX111 therapy for Sanfilippo syndrome type A, citing manufacturing observations.

The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and unnecessary delays in the regulatory process.